Erythropoietin (EPO) vs LL-37
Updated October 16, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Erythropoietin (EPO) and LL-37 (also searched as LL-37 vs Erythropoietin (EPO)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Erythropoietin (EPO) centers on healing, while LL-37 leans toward healing. On indexed research, Erythropoietin (EPO) is ahead (Erythropoietin (EPO): 38 studies, Human evidence; LL-37: 35, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Erythropoietin (EPO) is strongest for healing; LL-37 for healing.
- •Evidence: Erythropoietin (EPO) Human evidence (38 studies) vs LL-37 Human evidence (35).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Erythropoiesis | Anemia treatment
Erythropoietin (EPO) vs LL-37: side-by-side
| Metric | Erythropoietin (EPO) | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 38 | 35 |
| Research level | Well Studied | Well Studied |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0 | 5.0▲ |
| Muscle & body comp | 2.0▲ | 0.0 |
| Metabolic & appetite | 3.0▲ | 0.0 |
| Neuro & mood | 1.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 2.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Erythropoietin (EPO) | LL-37 |
|---|---|---|
| Mechanism | EPOR agonist | Disrupts microbial membranes, modulates immune responses |
| Route | Subcutaneous injection | — |
| Half-life | ~4–13 hours | — |
| Time to peak | ~5 hours | — |
| Duration of action | ~24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Erythropoietin (EPO)?
Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys in response to hypoxia. Its main function is to stimulate the production of red blood cells (erythropoiesis) in the bone marrow by binding to erythropoietin receptors (EPOR) on erythroid progenitor cells. This interaction activates various intracellular signaling pathways, including the JAK2/STAT5 pathway, which promotes cell survival, proliferation, and differentiation of erythroid progenitors.
Full Erythropoietin (EPO) profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response. It is produced by various cells, including epithelial cells and neutrophils, and exhibits a broad spectrum of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 interacts with a variety of pathogens, including bacteria, viruses, and fungi, contributing to the host's defense mechanisms.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Muscle | Erythropoietin (EPO) | 2.0/5 effect signal |
| Metabolic | Erythropoietin (EPO) | 3.0/5 effect signal |
| Neuro | Erythropoietin (EPO) | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Erythropoietin (EPO) and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Erythropoietin (EPO) vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Erythropoietin (EPO) has 38 approved studies indexed (Human evidence), and LL-37 has 35 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Erythropoietin (EPO) or LL-37 better?
It depends on your goal. Erythropoietin (EPO) is strongest for healing; LL-37 for healing. Erythropoietin (EPO) has more indexed studies (38). See the goal-by-goal breakdown above.
Is Erythropoietin (EPO) or LL-37 better for weight loss?
Erythropoietin (EPO) shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Erythropoietin (EPO) or LL-37 better for muscle?
Erythropoietin (EPO) leads on the muscle & body-composition axis (2.0/5).
Which has more research, Erythropoietin (EPO) or LL-37?
Erythropoietin (EPO) has 38 approved studies indexed (Human evidence); LL-37 has 35 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Erythropoietin (EPO) and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Erythropoietin (EPO) vs LL-37?
Erythropoietin (EPO): no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Erythropoietin (EPO) or LL-37 FDA-approved?
Erythropoietin (EPO) is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than Erythropoietin (EPO)?
For healing, LL-37 has the edge; for healing, Erythropoietin (EPO) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Erythropoietin (EPO) and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 16, 2026.